This course was presented in person at World Sleep 2025 in Singapore.

To access the session recording, navigate to the content tab and click the view video button. 

Session Schedule

Find a specific presentation in the course by navigating to the timestamp indicated below.

0:00:00
Introduction

0:00:57
Overview: From CPAP treatment to the first medicine for OSA patients with obesity
Ding Zou (Sweden)

0:12:20
Kairos positive airway pressure (KPAP) for OSA treatment
William Noah (United States)

0:28:13
Intra-Oral sensor systems for monitoring mandibular advancement device therapy
Peter Cistulli (Australia)

0:44:24
Targeting upper airway muscle dysfunction in OSA: A new frontier in treatment
Ana Sanchez-Azofra (United States)

0:58:00
Effect of orofacial myofunctional therapy with autofeedback in patients with newly diagnosed OSA: The OMTAOSA RCT
Diana Dobran Hansen (Norway)

1:09:15
Question and answer

Summary
This symposium will highlight groundbreaking advancements in obstructive sleep apnea (OSA) treatment, showcasing original work from recent publications, in-press articles, and FDA-pending applications. Featuring five presentations by distinguished academics and emerging investigators, the session aims to provide a comprehensive overview of innovative approaches to OSA management.

Introduction:
Dr. Ding Zou will open the symposium with an overview of the field based on his e-book (Novel Technologies in the Diagnosis and Management of Sleep-disordered Breathing, Frontiers. 2024) and recent publication, titled Breaking Ground: From CPAP Treatment to the First Medicine for OSA Patients with Obesity (Curr Pulmonol Rep, 2025). This work explores the transition from traditional CPAP therapies to pharmacological treatments for OSA, setting the stage for subsequent discussions.

KariosPAP (KPAP) Therapy:
Dr. William Noah will present the latest developments in the Karios Positive Airway Pressure (KPAP) therapy, which features an innovative two-step pressure drop during inspiration and gradual restoration during expiration. Published studies, such as those by White et al. (Sleep Med, 2024), Messineo et al. (Front. Sleep, 2024) and Noah et al. (J Clin Sleep Med, 2024), have shown KPAP's efficacy and superior comfort compared to traditional PAP therapies, with potential to resolve treatment-emergent central sleep apnea at lower pressures. New results combining KPAP with an APAP algorithm for optimal pressure management will be presented for the first time.

Intraoral Sensor Systems for MAD Therapy:
Dr. Peter Cistulli will introduce an FDA-pending intraoral sensor system designed to enhance the monitoring of mandibular advancement device (MAD) therapy. This system enables precise evaluation of jaw movement and its therapeutic effects on OSA. Insights from studies by Mohammadieh et al. (Front. Sleep, 2023) and Pépin et al. (Ann Am Thorac Soc, 2024) highlight the system's potential to refine MAD therapy and patient adherence through personalized treatment.

Pharmacotherapy in OSA:
Pharmacological approaches to OSA management, especially addressing the sleep-related neuromuscular dysfunction, are being heavily investigated. Targeting the reductions in neural input and/or augmenting dilator muscle responsiveness during sleep to maintain pharyngeal patency has shown promising potential in both preclinical and clinical studies. Dr. Ana Sanchez Azofra will highlight the emerging pharmacotherapy landscape targeting this key pathophysiological trait and share updates on AD109, a combination of a novel antimuscarinic (aroxybutynin) and a selective norepinephrine reuptake inhibitor (atomoxetine) that is in 2 ongoing Phase 3 clinical trials. This investigational therapy addresses the neuromuscular root cause of OSA and offers a different approach from currently available therapies.


The Sleep Revolution and OMTAOSA Trial:
Dr. Diana Dobran Hansen will present preliminary data from the Orofacial Myofunctional Therapy with Autofeedback for Obstructive Sleep Apnea (OMTAOSA) trial, part of the Sleep Revolution, a large pan-European project funded by Horizon 2020. This randomized controlled trial (NCT06079073) explores how myofunctional therapy with real-time feedback can improve OSA outcomes, emphasizing participatory healthcare and technological innovation.

Through these diverse presentations, attendees will gain valuable insights into the latest advancements in OSA treatment. Topics will range from innovative PAP algorithms and intraoral monitoring systems to pharmacological therapies and technological solutions. Collectively, these advancements represent a future of more personalized, precise, and effective management strategies, offering transformative improvements in patient outcomes and quality of life.